<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00268476</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000455008</org_study_id>
    <secondary_id>MRC-STAMPEDE</secondary_id>
    <secondary_id>EU-205102</secondary_id>
    <secondary_id>PR08</secondary_id>
    <secondary_id>ISRCTN78818544</secondary_id>
    <secondary_id>2004-000193-31</secondary_id>
    <nct_id>NCT00268476</nct_id>
  </id_info>
  <brief_title>Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy</brief_title>
  <acronym>STAMPEDE</acronym>
  <official_title>STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Research Council</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of this trial, which is called STAMPEDE, is to assess novel approaches for
      the treatment of men with prostate cancer who are starting long-term ADT for the first time,
      termed hormone-naïve prostate cancer. This trial aims to see if we can improve the way in
      which prostate cancer is currently managed, either by adding new treatments to the standard
      approach or by modifying the type of hormone therapy aiming to improve quality-of-life by
      reducing the side effects of treatment. Each new treatment approach is compared against a
      control arm receiving the current standard treatments. We aim to identify treatment
      strategies that enable men to live longer, or as long but with an improved quality-of-life,
      as well as offering value for money for the health service.

      Since opening to accrual in Oct-2005, the trial has tested many ways of treating prostate
      cancer and some results are now already known. More than 10,000 men will join the trial with
      answers becoming available throughout the trial. New patients joining the trial from Protocol
      version 17.0 onwards (activated in December 2018) may be eligible to join one of two
      treatment comparisons, metformin (treatment group K; the &quot;metformin comparison&quot;) and
      transdermal oestradiol (treatment group L; the &quot;transdermal oestradiol comparison&quot;). A
      computer program will be used to allocate which treatment each participant receives, using a
      chance process.

      Summary of the research arms in STAMPEDE trial platform Summary of research treatment groups
      currently open to recruitment (June 2017)

        1. Metformin (Arm K): This anti-diabetic medication is proposed to have both anti-cancer
           effects and may help prevent the adverse metabolic effects of long-term ADT. STAMPEDE
           will investigate whether adding metformin to the current standard-of-care for
           non-diabetic men can improve all-cause survival.

        2. Transdermal oestradiol (Arm L): This is an alternative form of hormone treatment which
           has been shown to suppress testosterone as effectively as standard ADT and avoid some of
           the side-effects. It may also help to avoid the adverse metabolic effects and fatigue
           and therefore improve overall quality of life compared with standard forms of ADT.
           STAMPEDE will investigate whether transdermal oestradiol can treat the cancer as well as
           current standard forms of ADT.

        3. Control group (Arm A): Patients allocated to this group receive the current
           standard-of-care ADT +/- RT +/- docetaxel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STAMPEDE (also known as MRC PR08) is a multi-arm multi-stage (MAMS) randomised controlled
      trial recruiting in the UK and Switzerland. It aims to evaluate multiple therapeutic
      strategies in the management of high-risk locally advanced and metastatic hormone-naïve
      prostate cancer. Each novel treatment strategy is compared against a single, contemporaneous
      control arm. When the trial originally opened in 2005 there were 6 research arms enabling 5
      randomised comparisons. Each comparison is evaluated in stages with pre-planned interim
      analyses after which recruitment may be halted should the experimental treatment fail to
      reach a &quot;hurdle&quot; of activity. Patient data from all arms and all stages are, however,
      included in the final analyses of the primary outcome measure, even if the investigational
      arm did not proceed to the final stage.

      Providing sufficient activity is demonstrated, recruitment continues to the final stage and
      then an assessment of efficacy is determined based on the primary outcome of overall
      survival. Patient data from all arms and all stages are included in the final analyses of the
      primary outcome measure, even if the investigational arm did not proceed to the final stage.

      The original comparisons which have all now been reported, evaluated a bisphosphonate
      (zoledronic acid), a cytotoxic chemotherapeutic agent (docetaxel) and a cyclooxygenase (Cox
      2) inhibitor (celecoxib), as single agents or combinations. Since the start of the trial, a
      number of new research arms have been added to STAMPEDE over time to evaluate: abiraterone, a
      steroid synthesis inhibitor; prostate radiotherapy for patients with newly diagnosed
      metastatic disease; enzalutamide, an inhibitor of androgen receptor signalling, given with
      abiraterone; and metformin, an anti-diabetic medication and transdermal oestradiol, to be
      given as an alternative form of ADT.

      Objectives:

      Primary

      To compare the safety and efficacy of novel therapeutic strategies against the current
      standard-of-care for men with high-risk locally advanced or metastatic prostate cancer
      starting long-term ADT for the first time.

      Outline: This is a randomised, controlled, multi-centre MAMS trial platform. Patients are
      current randomised to 1 of 3 arms: control group (arm A), metformin treatment group (arm K)
      and transdermal oestradiol (Arm L). The other arms are all closed to recruitment with results
      known for all the original comparisons and awaited for others added since the trial
      commenced.

      Patient population: STAMPEDE recruits both men with high-risk locally advanced prostate
      cancer and men with metastatic prostate cancer, all of whom must be starting long-term ADT
      for the first time. Patients who received previous radical treatment and are now relapsing
      with high-risk features are also eligible.

      Follow-up: All patients are follow-up life long

      Sub-studies: There are several translational sub-studies ongoing as part of STAMPEDE.
      Participation is optional. These currently include several translational sub-studies
      involving sample collection: saliva collection for germline DNA analysis, sequential
      circulating tumour DNA analysis and FFPE tumour block retrieval for DNA and RNA analysis.
      Other sub-studies include a QOL sub-study and an imaging sub-study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2005</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multi-arm Multi-Stage</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1:Not applicable</time_frame>
    <description>Time to mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Failure-free survival</measure>
    <time_frame>1:Not applicable</time_frame>
    <description>Time to progression event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost effectiveness by EuroQol</measure>
    <time_frame>1:Not applicable</time_frame>
    <description>Comparison of additional costs and survival gain to SOC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL) by EORTC QOL Questionnaire C30 and prostate specific 25-item</measure>
    <time_frame>1:Not applicable</time_frame>
    <description>Determination of changes in quality of life with interventions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>1:Not applicable</time_frame>
    <description>Incidence and types of IMP toxicities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal related events</measure>
    <time_frame>1:Not applicable</time_frame>
    <description>Incidence and types of skeletal related events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical failure</measure>
    <time_frame>1:Not applicable</time_frame>
    <description>For the purposes of the STAMPEDE trial, a unique threshold PSA value for biochemical failure is calculated for each patient, referred to as the PSA progression value.
A. If PSA nadir in the 24 weeks following randomisation is more than 4ng/ml and more than 50% of the pre-treatment PSA level - immediate treatment failure.
B. If PSA nadir in the 24 weeks following randomisation is less than or equal to 50% of the pre-treatment PSA level but remains above 4ng/ml - treatment failure will be defined as a rise of 50% above the nadir level.
C. If PSA nadir in the 24 weeks following randomisation is less than or equal to 4ng/ml - treatment failure will be defined as at least 50% rise above the nadir value and also above 4ng/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>1:Not applicable</time_frame>
    <description>Incidence of mortality without a progression event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymph node progression</measure>
    <time_frame>1:Not applicable</time_frame>
    <description>Incidence and severity of lymph node events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastases</measure>
    <time_frame>1:Not applicable</time_frame>
    <description>Incidence and severity of distant metastatic events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment for progression</measure>
    <time_frame>1:Not applicable</time_frame>
    <description>Identifying the treatments used in second line treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific survival</measure>
    <time_frame>1:Not applicable</time_frame>
    <description>Mortality attributed to Prostate Cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-prostate cancer death</measure>
    <time_frame>1:Not applicable</time_frame>
    <description>Mortality not attributed to Prostate Cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic effects</measure>
    <time_frame>1:Not applicable</time_frame>
    <description>Incidence and severity of effects on metabolic systems</description>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Anticipated">11200</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Androgen Deprivation Therapy [ADT] (plus Radiotherapy for newly-diagnosed non-metastatic disease, plus or minus Docetaxel, plus or minus Abiraterone)[Control]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Zoledronic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(ADT + zoledronic acid) NO LONGER RECRUITING</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(ADT + docetaxel + prednisolone) NO LONGER RECRUITING</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D: Celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(ADT + celecoxib) NO LONGER RECRUITING</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E: Zoledronic Acid &amp; Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(ADT + zoledronic acid + docetaxel + prednisolone) NO LONGER RECRUITING</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm F: Zoledronic Acid &amp; Celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(ADT + zoledronic acid + celecoxib) NO LONGER RECRUITING</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm G: Abiraterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(ADT + abiraterone acetate + prednisolone) NO LONGER RECRUITING</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm H: M1 RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(ADT + radiotherapy to the prostate) NO LONGER RECRUITING</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm J: Abiraterone * Enzalutamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(ADT + abiraterone + enzalutamide + Prednisolone) NO LONGER RECRUITING</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm K: Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(ADT + Metformin) RECRUITING</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm L: tE2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Transdermal oestradiol) RECRUITING</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <arm_group_label>Arm D: Celecoxib</arm_group_label>
    <arm_group_label>Arm F: Zoledronic Acid &amp; Celecoxib</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>Arm C: Docetaxel</arm_group_label>
    <arm_group_label>Arm E: Zoledronic Acid &amp; Docetaxel</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <arm_group_label>Arm C: Docetaxel</arm_group_label>
    <arm_group_label>Arm E: Zoledronic Acid &amp; Docetaxel</arm_group_label>
    <arm_group_label>Arm G: Abiraterone</arm_group_label>
    <arm_group_label>Arm J: Abiraterone * Enzalutamide</arm_group_label>
    <other_name>Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADT</intervention_name>
    <arm_group_label>Arm A: Standard of Care</arm_group_label>
    <arm_group_label>Arm B: Zoledronic Acid</arm_group_label>
    <arm_group_label>Arm C: Docetaxel</arm_group_label>
    <arm_group_label>Arm D: Celecoxib</arm_group_label>
    <arm_group_label>Arm E: Zoledronic Acid &amp; Docetaxel</arm_group_label>
    <arm_group_label>Arm F: Zoledronic Acid &amp; Celecoxib</arm_group_label>
    <arm_group_label>Arm G: Abiraterone</arm_group_label>
    <arm_group_label>Arm H: M1 RT</arm_group_label>
    <arm_group_label>Arm J: Abiraterone * Enzalutamide</arm_group_label>
    <arm_group_label>Arm K: Metformin</arm_group_label>
    <other_name>Androgen Deprivation Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic Acid</intervention_name>
    <arm_group_label>Arm B: Zoledronic Acid</arm_group_label>
    <arm_group_label>Arm E: Zoledronic Acid &amp; Docetaxel</arm_group_label>
    <arm_group_label>Arm F: Zoledronic Acid &amp; Celecoxib</arm_group_label>
    <other_name>Zometa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone</intervention_name>
    <arm_group_label>Arm G: Abiraterone</arm_group_label>
    <arm_group_label>Arm J: Abiraterone * Enzalutamide</arm_group_label>
    <other_name>Zytiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy to the prostate</intervention_name>
    <arm_group_label>Arm H: M1 RT</arm_group_label>
    <other_name>RT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <arm_group_label>Arm J: Abiraterone * Enzalutamide</arm_group_label>
    <other_name>Xtandi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>Arm K: Metformin</arm_group_label>
    <other_name>Metformin Hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transdermal Oestradiol</intervention_name>
    <arm_group_label>Arm L: tE2</arm_group_label>
    <other_name>Progynova TS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria Participants must fulfil both of the criteria in Section 1 or at least
        one criterion in Section 2 or at least one criterion in Section 3 of the protocol.
        Additionally, all patients must fulfil the criteria in Section 4.

          1. High-Risk Newly-Diagnosed Non-Metastatic Node-Negative Disease

             Both:

             •At least two of: T category T3/4, PSA≥40ng/ml or Gleason sum score 8-10

             •Intention to treat with radical radiotherapy (unless there is a contra-indication;
             exemption can be sought in advance of consent, after discussion with CTU)

             OR

          2. Newly-Diagnosed Metastatic Or Node-Positive Disease

             At least one of:

             •Stage Tany N+ M0

             •Stage Tany Nany M+

             OR

          3. Previously Radically Treated, Now Relapsing (Prior Radical Surgery And/or
             Radiotherapy)

             At least one of •PSA ≥4ng/ml and rising with doubling time less than 6 months

             •PSA ≥20ng/ml

             •N+

             •M+

             AND

          4. For All Patients

          1. Histologically confirmed prostate adenocarcinoma

          2. Intention to treat with long-term androgen deprivation therapy

          3. Treating clinician and patient should have decided if docetaxel is to be part of the
             standard-of-care prior to randomisation

          4. Fit for all protocol treatment1 and follow-up, WHO performance status 0-22

          5. Have completed the appropriate investigations prior to randomisation

          6. Adequate haematological function: neutrophil count &gt;1.5x109/l and platelets &gt;100x109/l

          7. Adequate renal function, defined as GFR &gt;30ml/min/1.73m2

          8. Serum potassium ≥3.5mmol/L

          9. Written informed consent

         10. Willing and expected to comply with follow-up schedule

         11. Using effective contraceptive method if applicable

          1. Medical contraindications to the trial medications are given in Section 6

          2. For WHO performance status definitions see Appendix A

        Exclusion Criteria

        Patients must not fulfil any of the criteria, below.

          1. Prior systemic therapy for locally-advanced or metastatic prostate cancer except as
             listed above

          2. Metastatic brain disease or leptomeningeal disease

          3. Abnormal liver functions consisting of any of the following:

               -  Serum bilirubin ≥1.5 x ULN (except for patients with Gilbert's disease, for whom
                  the upper limit of serum bilirubin is 51.3μmol/l or 3mg/dl)

               -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥2.5 x ULN

          4. Any other previous or current malignant disease which, in the judgement of the
             responsible clinician, is likely to interfere with STAMPEDE treatment or assessment

          5. Any surgery (e.g. TURP) performed within the past 4 weeks

          6. Patients with significant cardiovascular disease such that, in the investigator's
             opinion, the patient is unfit for any of the study treatments. This might include:

             •Severe/unstable angina

             •Myocardial infarction less than 6 months prior to randomisation

             •Arterial thrombotic events less than 6 months prior to randomisation

             •Clinically significant cardiac failure requiring treatment (NYHA II-IV)3

             •Cerebrovascular disease (e.g. stroke or transient ischaemic episode) less than 6
             months prior to randomisation

             •Patients with uncontrolled hypertension defined as systolic BP greater or equal than
             160mmHg or diastolic BP greater or equal than 95mmHg5

          7. Prior chemotherapy for prostate cancer (excluding patients receiving docetaxel as part
             of the new SOC)

          8. Prior exposure to long-term hormone therapy before randomisation

          9. Prior exposure to systemic treatment for prostate cancer (excluding hormone therapy)
             e.g. abiraterone and enzalutamide.

        3 NYHA classifications can be found in Appendix A

        5 Based on representative values, as judged by the investigator

        For Randomisation to the &quot;Metformin Comparison&quot;

        Patients with known diabetes mellitus are not eligible for randomisation to the &quot;metformin
        comparison&quot;. All non-diabetic patients require an HbA1c to be performed prior to
        randomisation (ideal timeline: within 8 weeks prior to randomisation), to confirm their
        non-diabetic status.

        In addition, an assessment of renal function is required to determine glomerular filtration
        rate (GFR). The method used to determine glomerular filtration rate may vary according
        local practice. Equations that either estimate glomerular filtration rate (eGFR) or
        creatinine clearance (CrCl) may be used and the same threshold value applies. In summary,
        additional inclusion criteria specifically for the &quot;metformin comparison&quot; are

        •HbA1c &lt;48mmol/mol (equivalent to &lt;6.5%)*

        •Adequate renal function, defined as GFR ≥45ml/min/1.73m2

          -  No history of lactic acidosis or pre-disposing conditions

          -  Not current or previous treatment with metformin

          -  No contra-indications to metformin

               -  Except Switzerland, please refer to SAKK appendix for local guidance

        Note that if the patient is known to be diabetic or the patient is found to have diabetes
        mellitus (i.e. HbA1c is 6.5% or higher) following screening, the patient is only eligible
        for randomisation if they meet all of the selection criteria for the &quot;transdermal
        oestradiol comparison&quot; (randomisation between Arms A and L only) All patients with abnormal
        baseline HbA1c (i.e. 6.0% or higher) should be informed and referred to their GP for
        further management.

        Where possible, the screening bloods, including HbA1c, should be performed prior to
        commencing SOC docetaxel. This is to reduce the likelihood of corticosteroid-related
        hyperglycaemia impacting on eligibility for the &quot;metformin comparison&quot;.

        For Randomisation To The &quot;Transdermal Oestradiol Comparison&quot;

        Patients who have any of the following are not eligible for the &quot;transdermal oestradiol
        comparison&quot;:

        •&gt;8 weeks of anti-androgen use

        •&gt;1 dose of monthly or 4 weekly LHRH agonist/antagonist

          -  Prior LHRH agonist injection with a stated duration of effect greater than 1 month
             •&gt;12 weeks since first dose of any hormone therapy

          -  Bilateral orchidectomy

          -  Cyproterone acetate started prior to randomisation

          -  Known porphyria

          -  Any history of deep vein thrombosis or pulmonary embolism confirmed radiologically

          -  Known thrombophilic disorder (e.g. Protein C, protein S, antithrombin deficiency)

        Note that patients unsuitable for the &quot;transdermal oestradiol comparison&quot; will only be
        eligible for randomisation if they meet all of the selection criteria for the &quot;metformin
        comparison&quot; and therefore may be allocated to control (arm A) or metformin (arm K) only.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas D. James, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>STAMPEDE Trial Team</last_name>
    <phone>+44 (0)20 7670 4700</phone>
    <email>mrcctu.stampede@ucl.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden</name>
      <address>
        <city>Chur</city>
        <state>Graubunden</state>
        <zip>CH-7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lausanne Centre Hospitalier Universitaire</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Winterthur Hospital</name>
      <address>
        <city>Winterthur</city>
        <state>Zurich</state>
        <zip>CH-8401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hirslanden Klinik Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital-Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Berne</city>
        <zip>CH-3010 Be</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Liestal Hospital</name>
      <address>
        <city>Liestal</city>
        <zip>CH-4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zuerich</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>City Hospital Triemli</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Berkshire Cancer Centre at Royal Berkshire Hospital</name>
      <address>
        <city>Reading</city>
        <state>Berkshire</state>
        <zip>RG1 5AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Bolton Hospital</name>
      <address>
        <city>Farnworth</city>
        <state>Bolton</state>
        <zip>BL4 0JR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wycombe General Hospital</name>
      <address>
        <city>High Wycombe</city>
        <state>Buckinghamshire</state>
        <zip>HP11 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Broomfield Hospital</name>
      <address>
        <city>Broomfield</city>
        <state>Chelmsford</state>
        <zip>CM1 7ET</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Countess of Chester Hospital</name>
      <address>
        <city>Chester</city>
        <state>Chesire</state>
        <zip>CH2 1UL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <state>County Durham</state>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cumberland Infirmary</name>
      <address>
        <city>Carlisle</city>
        <state>Cumbria</state>
        <zip>CA2 7HY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Devon District Hospital</name>
      <address>
        <city>Barnstaple</city>
        <state>Devon</state>
        <zip>EX31 4JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <state>Dorset</state>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dorset County Hospital</name>
      <address>
        <city>Dorchester</city>
        <state>Dorset</state>
        <zip>DT1 2JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Poole Hospital</name>
      <address>
        <city>Poole</city>
        <state>Dorset</state>
        <zip>BH15 2JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Castle Hill Hospital</name>
      <address>
        <city>Cottingham</city>
        <state>East Riding Of Yorkshire</state>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eastbourne District General Hospital</name>
      <address>
        <city>Eastbourne</city>
        <state>East Sussex</state>
        <zip>BN21 2UD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Conquest Hospital</name>
      <address>
        <city>Saint Leonards-on-Sea</city>
        <state>East Sussex</state>
        <zip>TN37 7PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>William Harvey Hospital</name>
      <address>
        <city>Ashford</city>
        <state>England</state>
        <zip>TN24 0LZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1233-633-331</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stoke Mandeville Hospital</name>
      <address>
        <city>Aylesbury</city>
        <state>England</state>
        <zip>HP21 8AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Basingstoke and North Hampshire NHS Foundation Trust</name>
      <address>
        <city>Basingstoke</city>
        <state>England</state>
        <zip>RG24 9NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>City Hospital (Birmingham)</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B18 7QH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sussex Cancer Centre at Royal Sussex County Hospital</name>
      <address>
        <city>Brighton</city>
        <state>England</state>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Burnley General Hospital</name>
      <address>
        <city>Burnley</city>
        <state>England</state>
        <zip>BB10 2PQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen's Hospital</name>
      <address>
        <city>Burton-upon-Trent</city>
        <state>England</state>
        <zip>DE13 0RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West Suffolk Hospital</name>
      <address>
        <city>Bury St. Edmunds</city>
        <state>England</state>
        <zip>IP33 2QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mid Cheshire Hospitals Trust- Leighton Hopsital</name>
      <address>
        <city>Crewe</city>
        <state>England</state>
        <zip>CW1 4QJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Darlington Memorial</name>
      <address>
        <city>Darlington</city>
        <state>England</state>
        <zip>DL3 6HX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Derbyshire Royal Infirmary</name>
      <address>
        <city>Derby</city>
        <state>England</state>
        <zip>DE22 3NE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Doncaster Royal Infirmary</name>
      <address>
        <city>Doncaster</city>
        <state>England</state>
        <zip>DN2 5LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Russells Hall Hospital</name>
      <address>
        <city>Dudley</city>
        <state>England</state>
        <zip>DY1 2HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Durham</name>
      <address>
        <city>Durham</city>
        <state>England</state>
        <zip>DH1 5TW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gloucestershire Royal Hospital</name>
      <address>
        <city>Gloucester</city>
        <state>England</state>
        <zip>GL1 3NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hereford County Hospital</name>
      <address>
        <city>Hereford</city>
        <state>England</state>
        <zip>HR1 2ER</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kidderminster Hospital</name>
      <address>
        <city>Kidderminster</city>
        <state>England</state>
        <zip>DY11 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Glenfield Hospital</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Aintree</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helen Rollason Cancer Care Centre at North Middlesex Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>N18 1QX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCL Cancer Institute</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WC1E 6DD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University College of London Hospitals</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WIT 3AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Withington Hospital</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 8LR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Shrewsbury Hospital</name>
      <address>
        <city>Shrewsbury</city>
        <state>England</state>
        <zip>SY3 8XQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stepping Hill Hospital</name>
      <address>
        <city>Stockport</city>
        <state>England</state>
        <zip>SK2 7JE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sunderland Royal Hospital</name>
      <address>
        <city>Sunderland</city>
        <state>England</state>
        <zip>SR4 7TP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Torbay Hospital</name>
      <address>
        <city>Torquay</city>
        <state>England</state>
        <zip>TQ2 7AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warrington Hospital NHS Trust</name>
      <address>
        <city>Warrington</city>
        <state>England</state>
        <zip>WA5 1QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West Cumberland Hospital</name>
      <address>
        <city>Whitehaven</city>
        <state>England</state>
        <zip>CA28 8JG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Albert Edward Infirmary</name>
      <address>
        <city>Wigan</city>
        <state>England</state>
        <zip>WN1 2NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Worcester Royal Hospital</name>
      <address>
        <city>Worcester</city>
        <state>England</state>
        <zip>WR5 1DD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Worthing Hospital</name>
      <address>
        <city>Worthing</city>
        <state>England</state>
        <zip>BN11 2DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Harlow</city>
        <state>Essex</state>
        <zip>CM20 1QX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen's Hospital</name>
      <address>
        <city>Romford</city>
        <state>Essex</state>
        <zip>RM7 0AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southend University Hospital NHS Foundation Trust</name>
      <address>
        <city>Westcliff-On-Sea</city>
        <state>Essex</state>
        <zip>SS0 0RY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South West Wales Cancer Institute At Singleton Hospital</name>
      <address>
        <city>Swansea</city>
        <state>Glamorgan</state>
        <zip>SA2 8QA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cheltenham General Hospital</name>
      <address>
        <city>Cheltenham</city>
        <state>Gloucestershire</state>
        <zip>GL53 7AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Bartholomews Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital - Woolwich</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>SE18 4QH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. George's Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Oldham Hospital</name>
      <address>
        <city>Oldham</city>
        <state>Greater Manchester</state>
        <zip>OL1 2JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>S016 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lister Hospital</name>
      <address>
        <city>Stevenage</city>
        <state>Hertfordshire</state>
        <zip>SG1 4AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Raigmore Hospital</name>
      <address>
        <city>Inverness</city>
        <state>Highland</state>
        <zip>IV2 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>Newport</city>
        <state>Isle Of Wight</state>
        <zip>PO30 5TG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Airedale General Hospital</name>
      <address>
        <city>Steeton</city>
        <state>Keighley</state>
        <zip>BD20 6TD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kent and Canterbury Hospital</name>
      <address>
        <city>Canterbury</city>
        <state>Kent</state>
        <zip>CT1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mid Kent Oncology Centre at Maidstone Hospital</name>
      <address>
        <city>Maidstone</city>
        <state>Kent</state>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth The Queen Mother Hospital</name>
      <address>
        <city>Margate</city>
        <state>Kent</state>
        <zip>CT9 4AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beatson Institute for Cancer Research - Glasgow</name>
      <address>
        <city>Glasgow</city>
        <state>Lanarkshire</state>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rosemere Cancer Centre at Royal Preston Hospital</name>
      <address>
        <city>Preston</city>
        <state>Lancashire</state>
        <zip>PR2 4QF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southport and Formby District General Hospital</name>
      <address>
        <city>Southport</city>
        <state>Merseyside</state>
        <zip>PR8 6PN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Cancer Centre at Mount Vernon Hospital</name>
      <address>
        <city>Northwood</city>
        <state>Middlesex</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Edinburgh Cancer Centre at Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <state>Midlothian</state>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle</city>
        <state>Newcastle-upon-Tyne</state>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Scarborough General Hospital</name>
      <address>
        <city>Scarborough</city>
        <state>North Yorkshire</state>
        <zip>YO12 6QL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre for Cancer Research and Cell Biology at Queen's University Belfast</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT9 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>King's Mill Hospital</name>
      <address>
        <city>Sutton-in-Ashfield</city>
        <state>Nottinghamshire</state>
        <zip>NG17 4JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Alexandra Hospital</name>
      <address>
        <city>Cosham</city>
        <state>Portsmouth</state>
        <zip>P06 3LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ayr Hospital</name>
      <address>
        <city>Ayr</city>
        <state>Scotland</state>
        <zip>KA6 6DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal United Hospital</name>
      <address>
        <city>Bath</city>
        <state>Somerset</state>
        <zip>BA1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bristol Haematology and Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <state>Somerset</state>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Musgrove Park Hospital</name>
      <address>
        <city>Taunton</city>
        <state>Somerset</state>
        <zip>TA1 5DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Weston General Hospital</name>
      <address>
        <city>Weston Super Mare</city>
        <state>Somerset</state>
        <zip>BS23 4TQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yeovil District Hospital</name>
      <address>
        <city>Yeovil</city>
        <state>Somerset</state>
        <zip>BA21 4AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Research Centre at Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>South Yorkshire</state>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Stoke University Hospital</name>
      <address>
        <city>Stoke-on-Trent</city>
        <state>Staffordshire</state>
        <zip>ST4 6QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ipswich Hospital</name>
      <address>
        <city>Ipswich</city>
        <state>Suffolk</state>
        <zip>IP4 5PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Luke's Cancer Centre at Royal Surrey County Hospital</name>
      <address>
        <city>Guildford</city>
        <state>Surrey</state>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - Sutton</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northern Centre for Cancer Treatment at Newcastle General Hospital</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <state>Tyne &amp; Wear</state>
        <zip>NE4 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Tyneside District Hospital</name>
      <address>
        <city>South Shields</city>
        <state>Tyne &amp; Wear</state>
        <zip>NE34 0PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bronglais General Hospital</name>
      <address>
        <city>Aberystwyth</city>
        <state>Wales</state>
        <zip>SY23 1ER</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Center at Velindre Hospital</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Good Hope Hospital</name>
      <address>
        <city>Sutton Coldfield</city>
        <state>West Midlands</state>
        <zip>B75 7RR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bradford Royal Infirmary</name>
      <address>
        <city>Bradford</city>
        <state>West Yorkshire</state>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Huddersfield Royal Infirmary</name>
      <address>
        <city>Huddersfield</city>
        <state>West Yorkshire</state>
        <zip>HD3 3EA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Great Western Hospital</name>
      <address>
        <city>Swindon</city>
        <state>Wiltshire</state>
        <zip>SN3 6BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Centre for Oncology</name>
      <address>
        <city>Bebington</city>
        <state>Wirral</state>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barnet General Hospital</name>
      <address>
        <city>Barnet</city>
        <zip>EN5 3DJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Colchester General Hospital</name>
      <address>
        <city>Colchester</city>
        <zip>CO4 5JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Forth Valley Hospital</name>
      <address>
        <city>Larbert</city>
        <zip>FK5 4WR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lincoln Hospital</name>
      <address>
        <city>Lincoln</city>
        <zip>LN2 5QY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Tees Hospital</name>
      <address>
        <city>Stockton-on-Tees</city>
        <zip>TS19 8PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New Cross Hospital</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.stampedetrial.org/</url>
    <description>Trial home page</description>
  </link>
  <reference>
    <citation>Sydes MR, Parmar MK, James ND, Clarke NW, Dearnaley DP, Mason MD, Morgan RC, Sanders K, Royston P. Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. Trials. 2009 Jun 11;10:39. doi: 10.1186/1745-6215-10-39.</citation>
    <PMID>19519885</PMID>
  </reference>
  <reference>
    <citation>Sydes MR, Parmar MK, Mason MD, Clarke NW, Amos C, Anderson J, de Bono J, Dearnaley DP, Dwyer J, Green C, Jovic G, Ritchie AW, Russell JM, Sanders K, Thalmann G, James ND. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials. 2012 Sep 15;13:168. doi: 10.1186/1745-6215-13-168.</citation>
    <PMID>22978443</PMID>
  </reference>
  <reference>
    <citation>Parker CC, Sydes MR, Mason MD, Clarke NW, Aebersold D, de Bono JS, Dearnaley DP, Ritchie AW, Russell JM, Thalmann G, Parmar MK, James ND. Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial. BJU Int. 2013 May;111(5):697-9. doi: 10.1111/bju.12087. Review.</citation>
    <PMID>23578233</PMID>
  </reference>
  <reference>
    <citation>Attard G, Sydes MR, Mason MD, Clarke NW, Aebersold D, de Bono JS, Dearnaley DP, Parker CC, Ritchie AW, Russell JM, Thalmann G, Cassoly E, Millman R, Matheson D, Schiavone F, Spears MR, Parmar MK, James ND. Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial. Eur Urol. 2014 Nov;66(5):799-802. doi: 10.1016/j.eururo.2014.05.038. Epub 2014 Jun 27.</citation>
    <PMID>24985962</PMID>
  </reference>
  <results_reference>
    <citation>James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Anderson J, Popert RJ, Sanders K, Morgan RC, Stansfeld J, Dwyer J, Masters J, Parmar MK. Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. BJU Int. 2009 Feb;103(4):464-9. doi: 10.1111/j.1464-410X.2008.08034.x. Epub 2008 Oct 8.</citation>
    <PMID>18990168</PMID>
  </results_reference>
  <results_reference>
    <citation>James ND, Sydes MR, Mason MD, Clarke NW, Anderson J, Dearnaley DP, Dwyer J, Jovic G, Ritchie AW, Russell JM, Sanders K, Thalmann GN, Bertelli G, Birtle AJ, O'Sullivan JM, Protheroe A, Sheehan D, Srihari N, Parmar MK; STAMPEDE investigators. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol. 2012 May;13(5):549-58. doi: 10.1016/S1470-2045(12)70088-8. Epub 2012 Mar 26. Erratum in: Lancet Oncol. 2013 Jan;14(1):e5.</citation>
    <PMID>22452894</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2005</study_first_submitted>
  <study_first_submitted_qc>December 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2005</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical Research Council</investigator_affiliation>
    <investigator_full_name>Medical Research Council</investigator_full_name>
    <investigator_title>Medical Research Council</investigator_title>
  </responsible_party>
  <keyword>Stage III Prostate Cancer</keyword>
  <keyword>Stage IV Prostate Cancer</keyword>
  <keyword>Recurrent Prostate Cancer</keyword>
  <keyword>Adenocarcinoma of the prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

